The Food and Drug Administration has approved a new drug called daraxonrasib for the treatment of pancreatic cancer. The drug targets tumors that carry a specific mutation in the KRAS gene, a common driver of this aggressive cancer. Daraxonrasib is designed for patients whose cancer has already spread or cannot be removed with surgery and who have tried other treatments.

Key Takeaways

  • Daraxonrasib is a targeted therapy that blocks the activity of a mutated KRAS protein, which fuels cancer growth.
  • The drug is approved for adults with pancreatic cancer that has a specific mutation called KRAS G12C.
  • Clinical trial results showed that daraxonrasib shrank tumors in about one third of patients who took it.
  • Common side effects include nausea, diarrhea, fatigue, and liver enzyme elevations.

How Daraxonrasib Works

Pancreatic cancer is often driven by mutations in the KRAS gene, which acts like an on switch for cell growth. For decades, scientists considered KRAS undruggable because its surface is smooth and lacks obvious pockets for a drug to latch onto. Daraxonrasib belongs to a new class of drugs that can bind to the mutated protein and lock it in an off position, stopping the signal that tells cancer cells to multiply.

The approval applies only to patients whose tumors have the KRAS G12C mutation, which occurs in about 1 to 2 percent of pancreatic cancer cases. While this is a small fraction, it represents thousands of patients each year in the United States who previously had no targeted treatment options.

Clinical Trial Results

The FDA based its decision on a single arm clinical trial that enrolled 148 patients with advanced pancreatic cancer who had already received at least one prior therapy. All patients had the KRAS G12C mutation. Researchers reported that daraxonrasib led to a confirmed tumor shrinkage in 33 percent of participants. The median duration of response was about 7 months.

These results are notable because pancreatic cancer is notoriously difficult to treat. Standard chemotherapy often provides only modest benefits, and many patients do not respond to it at all. Daraxonrasib offers a new mechanism of attack that works differently from chemotherapy, which may help patients whose cancer has stopped responding to other drugs.

Side Effects and Safety

Like all cancer drugs, daraxonrasib can cause side effects. The most common ones reported in the trial were nausea, diarrhea, fatigue, joint pain, and decreased appetite. Some patients experienced more serious side effects, including liver damage, lung inflammation, and heart rhythm abnormalities. Doctors are advised to monitor patients regularly for these issues and to adjust the dose or stop the drug if needed.

Because daraxonrasib is taken as a pill, it offers convenience compared to intravenous chemotherapy. Patients can take it at home, which may improve quality of life during treatment.

What This Means for Patients

The approval of daraxonrasib marks a step forward for precision medicine in pancreatic cancer, a disease that has lagged behind other cancers in terms of targeted therapies. Until recently, only a handful of drugs were available for pancreatic cancer, and most were chemotherapies with limited effectiveness.

Patients who want to know if daraxonrasib might be an option for them should talk to their oncologist about genetic testing of their tumor. The KRAS G12C mutation can be detected through a biopsy or a liquid biopsy that analyzes DNA from a blood sample. The drug is not suitable for patients without this specific mutation.

Frequently Asked Questions

Who is eligible for daraxonrasib?

Daraxonrasib is approved for adults with advanced or metastatic pancreatic cancer that has a KRAS G12C mutation and whose disease has progressed after at least one prior line of therapy. Patients must have a confirmed mutation through a genetic test approved by the FDA.

How is daraxonrasib taken?

The drug is taken orally as a tablet, usually once or twice daily depending on the dose prescribed by the doctor. Patients should follow their oncologist’s instructions carefully and not change the dose without medical advice.

What are the most common side effects?

The most frequently reported side effects include nausea, diarrhea, fatigue, joint pain, and decreased appetite. Some patients may also experience elevated liver enzymes, which require monitoring through regular blood tests.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.